Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.

Koichi Goto,Geoffrey R. Oxnard,Daniel Shao-Weng Tan,Herbert H. Loong,Todd Michael Bauer,Justin F. Gainor,Caroline E. McCoach,Oliver Gautschi,Benjamin Besse,Byoung Chul Cho,Nir Peled,Jared Weiss,Y Kim,Yuichiro Ohe,Atsushi Horiike,Keunchil Park,Xin Huang,Elizabeth Olek,Vivek Subbiah,Alexander Drilon

Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.

2020

3584Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-fusion+ no...

Keywords:

Lung cancer
Oncology
RET Fusion
in patient
non small cell
Pathology
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations